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PUF60 variants cause a syndrome of ID, short stature,
microcephaly, coloboma, craniofacial, cardiac, renal
and spinal features
Karen J Low1,2, Morad Ansari3, Rami Abou Jamra4, Angus Clarke5, Salima El Chehadeh6, David R FitzPatrick3,
Mark Greenslade7, Alex Henderson8, Jane Hurst9, Kory Keller10, Paul Kuentz11, Trine Prescott12,
Franziska Roessler4, Kaja K Selmer12, Michael C Schneider13, Fiona Stewart14, Katrina Tatton-Brown15,
Julien Thevenon11, Magnus D Vigeland12, Julie Vogt16, Marjolaine Willems17, Jonathan Zonana10,
DDD Study18 and Sarah F Smithson*,1,2
PUF60 encodes a nucleic acid-binding protein, a component of multimeric complexes regulating RNA splicing and transcription.
In 2013, patients with microdeletions of chromosome 8q24.3 including PUF60 were found to have developmental delay,
microcephaly, craniofacial, renal and cardiac defects. Very similar phenotypes have been described in six patients with variants
in PUF60, suggesting that it underlies the syndrome. We report 12 additional patients with PUF60 variants who were
ascertained using exome sequencing: six through the Deciphering Developmental Disorders Study and six through similar
projects. Detailed phenotypic analysis of all patients was undertaken. All 12 patients had de novo heterozygous PUF60 variants
on exome analysis, each conﬁrmed by Sanger sequencing: four frameshift variants resulting in premature stop codons, three
missense variants that clustered within the RNA recognition motif of PUF60 and ﬁve essential splice-site (ESS) variant. Analysis
of cDNA from a ﬁbroblast cell line derived from one of the patients with an ESS variants revealed aberrant splicing.
The consistent feature was developmental delay and most patients had short stature. The phenotypic variability was striking;
however, we observed similarities including spinal segmentation anomalies, congenital heart disease, ocular colobomata, hand
anomalies and (in two patients) unilateral renal agenesis/horseshoe kidney. Characteristic facial features included micrognathia,
a thin upper lip and long philtrum, narrow almond-shaped palpebral ﬁssures, synophrys, ﬂared eyebrows and facial
hypertrichosis. Heterozygote loss-of-function variants in PUF60 cause a phenotype comprising growth/developmental delay and
craniofacial, cardiac, renal, ocular and spinal anomalies, adding to disorders of human development resulting from aberrant RNA
processing/spliceosomal function.
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INTRODUCTION
In 2009, Verheij et al.1 reported overlapping interstitial microdele-
tions of chromosome 8q24 in two patients who had colobomata,
congenital heart defects, limb abnormalities, developmental delay
and seizures (MIM 615583). Dauber et al.2 later described ﬁve
patients who also had microdeletions of 8q24.3 and similar
phenotypes including ocular colobomata, microcephaly, develop-
mental delay, short stature, craniofacial, cardiac and renal defects.
All ﬁve patients had in common a 78-kb deleted region containing
three genes: SCRIB, NRBP2 and PUF60. A further patient with a
missense variant in PUF602 and a foetus with an 8q24.3 deletion
encompassing PUF60 occurring in association with an atrioven-
tricular septal defect, a hypoplastic aortic arch, facial dysmorphism
and other anomalies3 strongly implicated this single gene as the
cause of the phenotype.
The poly-U-binding splicing factor gene (PUF60) encodes a nucleic
acid-binding protein, which through interaction with other proteins
such as SF3B4, regulates pre-RNA splicing and transcription.2,4 In
2013 a single patient with an intragenic variant in PUF60 was
identiﬁed2 and recently ﬁve other cases have been reported.5 Here,
we present clinical and molecular data from 12 additional patients
with de novo variants in PUF60 identiﬁed via exome sequencing
undertaken for undiagnosed developmental disorders. The clinical
features we observed in these patients and those previously published
suggest that there is an emerging PUF60-related phenotype, although
this is variable and may be difﬁcult to recognize.
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METHODS
Patient ascertainment
Six of the affected patients were recruited via the Deciphering Developmental
Disorders (DDD) study6 (http: //www.ddduk.org) open to the UK NHS
Regional Genetics Services. Five patients were recruited via locally based exome
sequencing services by Clinical Geneticists in Norway, France and the United
States and one via an exome sequencing study for patients with Cornelia de
Lange Syndrome (CdLS; MIM 122470).6 All patients were assessed by their
Clinical Geneticist who assisted with systematic detailed phenotyping. Patient
growth centiles and z-scores were calculated using the UK WHO data (http:
//www.rcpch.ac.uk/growthcharts).
Genomic analysis
Trio-based exome sequencing was undertaken for the six affected patients and
their parents were identiﬁed via the DDD study.7 High‐resolution analysis for
copy number abnormalities using array‐based comparative genomic hybridiza-
tion was also performed. Putative de novo variants were identiﬁed from exome
data using the DeNovoGear software8 and then validated by targeted Sanger
sequencing. For patients 7–12, alternative but similar trio exome sequence
approaches were used, for example, for patient 10 a proband-based exome
sequencing as described previously,8 for patient 11 exome capture with Nextera
Rapid Capture Exome Kit (Illumina Inc., San Diego, CA, USA) and sequencing
with HiSeq4000 (Illumina). For patient 12, Agilent Clinical Research Exome Kit
(Agilent Technologies, Santa Clara, CA, USA) identiﬁed exonic and periexonic
fragments, followed by massive parallel next-generation sequencing. Analysis of
exome data was undertaken with DeNovoGear9 or FILTUS,10 and for patient 11,
raw data was processed using an end-to-end in-house database. Identiﬁed
variants were annotated using standard databases and were ﬁltered based on the
established criteria. Detailed descriptions of the wet and dry laboratory pipelines
are published elsewhere.11 For patient 12, analysis was performed with a
custom-developed Xome Analyser (Gene Dx, Bethesda, MD, USA). Mean depth
of coverage for the analysis was x121; and quality threshold (≥10x) was achieved
for 95.5% of the target sequence. As for DDD patients, signiﬁcant variants were
conﬁrmed by targeted Sanger sequencing. Variant data has been submitted to
ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) – submission ID SUB2319251.
Analysis of aberrant PUF60 splicing
Dermal ﬁbroblasts were obtained from patient 8 (3781–3781) by skin punch
biopsy and cultured in amnioMAX C-100 complete medium (Life Technolo-
gies, Carlsbad, CA, USA) as described previously.12 RNA was extracted from
primary skin-derived ﬁbroblast cell lines from patient 8 (3781–3781) and two
sex-matched controls using RNeasy Kit (Qiagen, Hilden, Germany) and treated
with DNAseI to eliminate genomic DNA, according to the manufacturer’s
instructions. Complementary DNA (cDNA) synthesis was carried out using
random oligomer primers and AMV Reverse Transcriptase (Roche, Penzburg,
Germany). The cDNA samples were resolved on an E-Gel electrophoresis
system and extracted according to the manufacturer’s instructions (Thermo
Fisher Scientiﬁc, Waltham, MA, USA) to sequence the amplicons correspond-
ing to the normal and mutant alleles. Sequences of primers used for cDNA
ampliﬁcation and Sanger sequencing of PUF60 are available upon request.
RESULTS
The clinical features and PUF60 variants in the 12 patients compared
with the previously reported cases2,5 are presented in Table 1.
Variants
The distribution of the heterozygous de novo variants (DNV) is shown
in context of the genomic structure of PUF60 in Figure 1. Nine of
the DNV were predicted to cause loss-of function suggesting haplo-
insufﬁciency as the likely mutational mechanism. Four patients
(1 (DDD275875),13 5 (DDD270021), 9 and 11) had frameshift variants
resulting in early stop codons. Five patients (2 (DDD273705), 7 (who
had the most complex phenotype), 8 (3781–3781), 10 and 12) had
essential splice-site variants. In patient 8 (3781–3781), a de novo
c.604− 2A4C variant occurred in the exon 8 splice-acceptor site and
was predicted to alter splicing of PUF60 mRNA. The effect of this
variant was investigated as above: analysis of cDNA conﬁrmed
abnormal inclusion of the complete intron 7 in the mutant allele
resulting in an apparent in-frame inclusion of 39 amino acids in the
open reading frame of the transcript (Figure 2). It is thus not clear
whether this essential splice-site variant will result in complete loss of
function. Nonetheless, her phenotype is consistent with respect to
developmental delay, short stature and cardiac involvement. Patient 12
was the only one to have a variant outside of the exon 6–12 region.
The wild-type donor site is predicted to be disrupted resulting in
skipping of exon 1; however, little is known about the exon 1 function
(Human Splicing Finder score of − 31.86 – probably affecting splicing;
http://www.umd.be/HSF3/HSF.html).
Three patients in this study had missense variants located in regions
encoding one of the three RNA recognition motif (RRM) domains of
the protein (Alamut), c.541G4A(p.(Glu181Lys)) and c.475G4A(p.
(Asp159Asn)) are located in RRM1 and c.1472G4A(p.(Gly491Glu) in
RRM3. CADD scores14 are shown in Table 1 and support effect on
function of all three variants.
None of the PUF60 variants we identiﬁed are listed in the Exome
Variant Server, Exome Aggregation Consortium or the dbSNP
population databases.
Growth
Birthweight was normal except for patients 6 (DDD263362; Z-score
− 2.14), 8 (3781–3781; Z-score − 2.11) and 11 (Z-score − 3.24). Body
weight in childhood remained in the normal range in all patients apart
from patients 7 and 8 (3781–3781; Z-scores − 4.47 and − 3.52
respectively) in both of whom other growth parameters were also
signiﬁcantly reduced. Nine patients had short stature deﬁned as height
below 5th centile and ﬁve had Z-scores below − 2. Head circumference
was proportionate to stature, apart from in ﬁve patients (1 (DDD2
75875), 6 (DDD263362), 7, 10 and 11) who had true microcephaly
(Z-scores − 2.48, − 4.22, − 2.09, − 2.99, − 2.53 respectively).
Musculoskeletal
Skeletal abnormalities, especially in the spine, were seen in seven
patients. In patient 3 (DDD271317), there was fusion of the whole
vertebral bodies of C6 and C7 and the anterior part of C5 (Figure 3)
and the posterior spinous processes of T6, T7 and T1 were unusually
prominent. His cervical spine stability requires neurosurgical mon-
itoring. Patient 7 had several cervical and thoracic hemivertebrae,
spina biﬁda, thoracic kyphosis, bilateral rudimentary ribs at C7 and
pectus excavatum (possibly exacerbated by sternotomy during cardiac
surgery). In patient 9, the conus terminated at the L2-L3 disc space
and the ﬁlum, 2 mm in width, extended from L3 to S2 associated with
posterior osseous dysraphism of the sacrum. Patients 6 (DDD263362),
10 and 12 had pectus excavatum. Patient 1 (DDD275875) had a lower
thoracic scoliosis and pes planus. He also had shoulder subluxation
and generalized joint laxity, which was a common feature in the
cohort. Patients 2 (DDD273705), 7, 9, 10 and 12 also had joint
hypermobility; in one case this was associated with bilateral hip and
interphalangeal joint dislocations. Digital anomalies in the group
included unilateral preaxial polydactyly of the left hand with a broad
proximal phalanx and duplicated distal phalanx (patient 7), short
broad hands with bilateral ﬁfth ﬁnger clinodactyly (patient 5
(DDD270021), left talipes, broad thumbs/halluces, ﬁfth ﬁnger clin-
odactyly, 2–3 toe syndactyly with an overriding second toe on the left
(patient 6 (DDD263362)) and bilateral hypoplasia of the ﬁfth ﬁngers
(patient 9).
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Auditory
Two patients had very narrow and easily occluded external
auditory meatus, two had severe otitis media with episodic
conductive hearing loss and two wear hearing aids for bilateral
conductive hearing loss.
Development
All patients had mild to moderate global developmental delay. Most
walked by 24 months and the latest did so by 30 months (patient 12
was not yet walking at 24 months). Most spoke their ﬁrst word by
30 months. Three patients had difﬁculties forming a pincer grip and
Figure 1 PUF60 gene diagram (above) indicating mutations found in our cohort which cluster in the second half of the coding region, apart from the single
variant in exon 1. Note recurrent splicing variant in exon 8. Below is pictured the known protein structure and location of RRM domains in relation to the
missense variants.
Figure 2 A de novo variant in PUF60 results in aberrant splicing at exon 8 splice-acceptor site. (a) The heterozygous, de novo PUF60 variant, c.604−2A4C
was identiﬁed in patient II:1 through trio-based exome sequencing of family 3781. (b) Sequencing of skin-derived cDNA from patient II:1 (family 3781)
showed normal splicing of exons 7 and 8 from one allele (top) and aberrant splicing with inclusion of the complete intron 7 from the mutant allele (bottom).
Black arrows show the position of the oligonucleotide primers used for cDNA ampliﬁcation and sequencing. The genomic context of the PUF60 gene is
shown, with exons indicated as black boxes. The location of the PUF60 c.604−2A4C variant in intron 7 is indicated by a dotted red arrow, with the Sanger
sequence trace from patient II:1 (family 3781) presented underneath. Variant nomenclature, exon numbering and the PUF60 messenger RNA sequence are
based on sequence accession numbers NM_078480.2 (mRNA) and NP_510965.1 (protein) and GenBank accession number NG_033879.1.
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with ﬁne motor coordination for activities such as handwriting. For
those who are currently of school age, all receive additional educa-
tional support and four attend either a special needs school or class.
Some episodes of difﬁcult or immature behaviour including attention
deﬁcit disorder, head-banging, self-injury or temper tantrums were
reported by parents of ﬁve patients.
Neurology
Patient 6 (DDD263362) had a stormy postnatal course during which
bilateral intraventricular haemorrhages occurred, later associated with
mild diplegia. An MRI brain scan showed periventricular leukomala-
cia, a thin corpus callosum and a cyst at the right cerebellopontine
angle. Patient 7 had a cardiac catheterization at 9 months of age and
following a right middle cerebral artery occlusion had a left-sided
hemiparesis and right facial weakness. A brain MRI scan of patient 11
showed mild periventricular gliosis. Patient 12 had an MRI scan,
which showed cerebral ventriculomegaly, partial agenesis corpus
callosum and loss of white matter in the periventricular regions.
Two patients have developed seizures.
Facial features
The facial features (Figure 4) included a short neck in ﬁve >patients, a
high forehead in six, micrognathia in four, a long philtrum in ﬁve,
bushy eyebrows in four and a thin upper lip in four patients. One
patient had synophrys and long eyelashes, another had bilateral
preauricular pits and a third, a right accessory auricle and skin tag
on the contralateral side of the neck. Two patients had facial features
initially suggesting CdLS. Two other patients were tested for mutations
in CREBBP and EP300 initially. One patient was tested for Cofﬁn–Siris
syndrome.
Other
Recurrent ocular, cardiac and renal features occurred and are
detailed in Table 1. Five patients had hypertrichosis of the face.
Two patients had macrodontia, one with ectopic teeth and one
Figure 3 Spinal features (above): AP x-ray of cervical spine of patient 7 demonstrating hemivertebrae (left) and 3D-CT reconstruction of cervical spine of
patient 3 demonstrating abnormalities of articulation of atlas with C1, vertebral bodies of C2/C3 and fusion of bodies of C6/C7/T1 and ocular features
(below): right iris coloboma in patient 5.
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early secondary dentition. Early feeding problems were very
common: in one patient a gastrostomy was required from 9 months
to 7 years of age and three patients were prone to aspiration
episodes and complications in infancy, this resolved in two of them
by late infancy.
DISCUSSION
The clinical and molecular data we observed in 12 patients suggest that
variants in PUF60 cause a syndrome characterized by short stature,
developmental delay, dysmorphic facial features and structural mal-
formations of the heart, eye and variably other organs. We are aware of
14 PUF60-related published cases: six with intragenic de novo missense
variants2,5 and eight with chromosome 8q24.3 deletions encompassing
PUF60.1–3 The pattern of their congenital malformations and pertur-
bation of growth and development shows some common themes.
Comparison of our patients with the six previously published for whom
data are available (Table 1) suggests that short stature, relative micro-
cephaly and developmental/cognitive delay are consistent ﬁndings. The
only exception is patient 12 who had macrocephaly, hydrocephalus and
normal stature, and in whom the variant was at the exon 1 boundary.
A previously published patient had an identical variant5 but their
phenotype was more typical, thus predictions on phenotype based on
position of speciﬁc variants are not possible at this stage. We observed
other similarities: a high proportion of cases overall had abnormal
segmentation of the vertebrae, which occurred at different levels of the
spine. One of our patients and two published patients5 had cervical
vertebral fusion/abnormal cervical spines. Other authors found more distal
lesions such as fusion of L5-S1, sacral dysplasia and agenesis of the
coccyx,2 and other patients, including patients 7, had hemivertebrae in the
thoracic and lumbar spine. We and others found minor developmental
abnormalities of the distal limbs, including brachydactyly of the ﬁfth
ﬁngers, clinodactyly and preaxial polydactyly. Ocular coloboma involving
the anterior segment of the eye, choroid and/or the retina, were
described in three previous as well as in two of our patients. Renal
malformations such as ectopic fused kidneys, pelvic kidney, a
unilateral polycystic kidney and renal hypoplasia or unilateral
agenesis have been observed,2,5 and in our cohort there was one
case each of a unilateral kidney and a horseshoe kidney. Five of our
patients had signiﬁcant congenital heart defects and other authors5
have also reported ventricular septal defects in combination with
truncus arteriosus coarctation or the aorta and bicuspid aortic
valve2 and atrioventricular septal defects and hypoplastic aortic
arch.3
While all 26 patients with deletions or variants of PUF60 had
developmental delay and intellectual disability, those with deletions
appear to be more severely affected.1,2 The reported microdeletions of
chromosome 8q24.3 may include other currently unknown genes that
contribute to neurological and cognitive development. It is interesting
that seizures were observed in our patients as well as in previous
reports. Feeding difﬁculties and recurrent respiratory infections were
common to some patients in both groups.
Previous authors commented on phenotypic similarity of PUF60-
deleted patients with SF3BF4-related Nager syndrome (MIM 154400)
and EFTUD2-related mandibulofacial dysostosis (MIM 610536) and
suggested that PUF60 deﬁciency can be considered within the spectrum
of craniofacial disorders resulting from spliceosome malfunction.15
However, coloboma, optic nerve hypoplasia and facial hirsutism have
not hitherto been reported in syndromes ascribed to spliceosomal
dysfunction. We and others noticed that some patients had features
reminiscent of CdLS, particularly where facial hypertrichosis and
prominent eyebrows were present. Comparison of the facial features
in all patients with PUF60 deletions or variants where data were
available indicated that micrognathia, a long philtrum and thin upper
lip, synophrys, preauricular pits and cranial asymmetry were common
ﬁndings. Additionally, two of our patients had very narrow external
auditory canals, consistent with abnormal branchial arch development
during embryogenesis, also thought to be a process disturbed in
mandibulofacial dysostosis and Nager syndromes; however, the facial
Figure 4 Faces of patients (1, 2, 3, 4,6, 7, 8, 9, 10 and 11) with PUF60 variants, illustrating the thin upper lip, long philtrum, micrognathia and the ﬂaring
of eyebrows and narrow almond-shaped palpebral ﬁssures, which are variably present. Patients 6 and 8 were assessed for CdLS and patients 7 and 10 had
CREBBP analysis because of facial similarities with Rubinstein–Taybi syndrome. Patient 9 was investigated for Cofﬁn–Siris syndrome.
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dysmorphology of patients with PUF60 variants is far more subtle than
in EFTUD2 and SF3B4-related phenotypes and mandibulofacial
dysostosis was not present in the patients we report. Furthermore, it
is interesting to note that none of the patients were clinically suspected
of a known spliceosomopathy. We conclude that the facial features
associated with PUF60 might be recognized independently, but the
diagnosis is more likely to be considered in a child with short stature,
developmental delay and additional malformations described.
There is accumulating evidence from this and other phenotypic
studies that PUF60 is important in human embryonic development.
PUF60 belongs to the RRM half pint family and contains three RRM
domains. Consistent with a developmental role, PUF60 encodes a
DNA- and RNA-binding protein that is involved in diverse nuclear
processes such as pre-mRNA splicing and regulation of transcription.
During pre-mRNA splicing, PUF60 interacts with U2AF2 to promote
splicing of an intron with a weak 3' splice site4 and has a role in
alternative splicing.2 PUF60 is one of the non-core components that
can ally with the U2 spliceosomal small nuclear ribonucleoprotein
particles, or U2 spliceosome complex.16 Finally, PUF60 has been
associated with the transcriptional repression of MYC through
association with FUBP1. The mechanism by which reduced PUF60
expression affects cellular functions are not yet understood and
beyond the scope of this study. It is an interesting though that the
PUF60-related phenotype is more diverse than some others deter-
mined by spliceosomal genes, where very speciﬁc and recognizable
malformations arise.17 Presumably, speciﬁc tissues are PUF60 dose-
sensitive at speciﬁc times during early human development.
The similar phenotypes in 8q24.3 deletions encompassing the entire
PUF60 gene and the point variants in our series, including both
missense and null variants, suggest that haploinsufﬁciency is the
common mechanism in all. Loss-of-function variants are predicted to
result in altered dosage of different PUF60 isoforms and consequently
abnormal splicing of target genes.2 Variants in this gene would
therefore be expected to have widespread phenotypic effects. Previous
researchers found that patient-derived cells demonstrated expression
of a truncated speciﬁc isoform of PUF60.2 They also showed that
suppression of puf60 in developing zebraﬁsh resulted in reduced body
length, microcephaly, craniofacial defects and cardiac anomalies.
Additionally, they found evidence that suppression of the scrib gene
(syntenic and adjacent to PUF60 in humans) caused defects such as
colobomata and renal anomalies, and thus concluded that some
features of the 8q24.3 deletion phenotype might be due to this
contiguous gene. Our data together with the other six reported cases
suggest that PUF60 deﬁciency itself could account for these features in
humans. We anticipate that more patients with PUF60 variants will be
described, which, in association with functional studies, will help to
delineate the characteristics of this complex syndrome.
CONCLUSIONS
Chromosome 8q24.3 deletions have been associated with a phenotype
encompassing microcephaly and short stature, developmental delay,
colobomata, craniofacial, skeletal, cardiac and renal anomalies. Our
ﬁndings demonstrate a very similar pattern of mild or moderate
intellectual disability and physical characteristics observed in patients
with variants in PUF60. We suggest that loss or reduction of
expression of PUF60 results in a complex human phenotype with
subtle facial features and a consistent pattern of congenital malforma-
tions, especially involving the heart and spine.
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